Screener
Syndax Pharmaceuticals SNDX Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept sndx:AccountsPayableAndAccruedExpenses.
The source filing: Syndax Pharmaceuticals’s 10-K, filed February 26, 2026. Open the filing →
- Filed
- Feb 26, 2026, 4:04 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-076536
FAQ
- What is Syndax Pharmaceuticals's accounts payable and accrued expenses?
- Syndax Pharmaceuticals (SNDX) reported accounts payable and accrued expenses of $0 in Q4 2025.
- What is the long-term trend for Syndax Pharmaceuticals's accounts payable and accrued expenses?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's accounts payable and accrued expenses has grown at a -100.0% compound annual growth rate (CAGR), from $131K to $0.
- What does accounts payable and accrued expenses mean?
- This represents the aggregate of short-term obligations owed to suppliers, vendors, and service providers, combined with accrued liabilities for services received but not yet invoiced. It serves as a measure of the company's short-term working capital management.
Ask your AI about Syndax Pharmaceuticals's accounts payable and accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude